Answers are grounded in this paper and cite their sources.
Observational study finds highest hepatocellular carcinoma risk in chronic hepatitis B patients without steatosis but with cardiometabolic risk factors, suggesting improved risk assessment strategies.
Among patients with CHB receiving nucleos(t)ide analogs, those without SLD having ≥2 CMRFs had the highest risk of HCC. Thus, steatosis and metabolic burden should be incorporated into precision risk stratification.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: